# Optimal Dose of Antivenom for Daboia Siamensis Envenomings

> **NCT04210141** · PHASE2 · SUSPENDED · sponsor: **Myanmar Oxford Clinical Research Unit** · enrollment: 200 (estimated)

## Conditions studied

- Daboia Siamensis Envenoming

## Interventions

- **BIOLOGICAL:** lyophilized BPI viper antivenom

## Key facts

- **NCT ID:** NCT04210141
- **Lead sponsor:** Myanmar Oxford Clinical Research Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-04
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** due to current political circumstances in study site area.
- **Last updated:** 2024-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04210141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04210141, "Optimal Dose of Antivenom for Daboia Siamensis Envenomings". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04210141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*